Advanced Enzyme Technologies Ltd. Share Price

Advance Enzyme Technologies Buyback

* ADVENZYMES has approved a share buyback at ₹500 per share through the open-market route. * The buyback price provides a potential positive signal for shareholder value, while reducing the company’s outstanding share capita

Advent Hotels - Prestige Estates JV

1. Strategic Joint Venture for Sahar Project: Advent Hotels will sell a 50% stake in its hotel SPV (ACHIL) to Prestige Estates Projects for ₹504 crore, converting ACHIL into a 50:50 joint venture to jointly develop the Sahar hospitality project. 2. Positive for Growth & Capital Efficiency: The transaction unlocks ₹504 crore in capital for Advent Hotels while bringing in Prestige’s execution expertise and financial strength, reducing project risk and supporting faster development of the premium hotel asset. PRESTIGE

Advanced Enzyme Infuses ₹2.5 Million into Wholly-Owned Subsidiary ANPL

Advanced Enzyme Technologies Limited has made an additional investment of ₹2.5 million in its wholly-owned subsidiary, Advanced Nutrazyme Private Limited (ANPL). The capital infusion was executed through the subscription of a rights issue comprising 2,50,000 equity shares with a face value of ₹10 each. Post-Investment Position: Following this transaction, Advanced Enzyme's total investment in ANPL has increased to ₹3 million, bringing its total shareholding to 3,00,000 equity shares. Strategic Context: Internal Restructuring: As ANPL is already a 100% subsidiary, this rights issue does not alter the ownership structure or control. Balance Sheet Strengthening: The move is designed to bolster the subsidiary's financial position, providing it with the necessary capital to support its operational requirements and growth initiatives in the specialized nutrazyme segment. Consolidated Impact: Being an internal transfer of funds, this transaction will not materially impact Advanced Enzyme's consolidated financial statements. Outlook: This routine capital injection underscores the parent company's continued financial commitment to ANPL's strategic roadmap. Investors will view this as a standard operational funding exercise aimed at scaling the subsidiary's business capabilities. ADVENZYMES

ADVENZYMES

ADVANCED ENZYMES INCREASES INVESTMENT IN WHOLLY OWNED SUBSIDIARY 🧬💰 • 🏢 Completed additional investment of ₹25 lakh in wholly owned subsidiary Advanced Nutrazyme Pvt. Ltd. (ANPL) • 📈 Investment made through subscription to 2,50,000 equity shares of ₹10 each under a rights issue • 💵 Total investment in ANPL now stands at ₹30 lakh • 📊 Holding represented by 3,00,000 equity shares of ₹10 each • 🎯 Capital infusion aimed at supporting subsidiary's growth and operational requirements • 🤝 ANPL remains a 100% owned subsidiary of Advanced Enzyme Technologies 🟢 Impact: Positive (Additional capital support reflects commitment to subsidiary growth, though the investment size is relatively small and not materially impactful on consolidated financials.)

Stocks In News 11 May 2026

CMSINFO – Stock may remain active after quarterly updates, with investors watching margin trends and cash management business outlook. ADVENZYMES – Q4 results and management commentary on export demand and pharma/nutrition business growth could drive movement. Niva Bupa Health Insurance – In focus after earnings update; market will track premium growth, profitability, and claim ratio trends. Oberoi Realty – Reported strong Q4 numbers along with dividend announcement, which may support positive sentiment. Bank of India – Investors will react to quarterly earnings, asset quality, loan growth, and NIM outlook. Swiggy – Key stock after Q4 results; focus remains on revenue growth, losses, and quick commerce performance. ABB – Market eyeing earnings, order inflows, and industrial automation demand outlook. Tata Consumer Products – Investors will watch volume growth, margin performance, and future demand commentary. Overall: Market action today is likely to stay results-driven, with earnings reactions and management guidance setting the tone.

ADVENZYMES : Q4 CONS NET PROFIT 430M RUPEES VS 265M (YOY) || Q4 REVENUE 2.04B RUPEES VS 1.7B (YOY) ADVANCED ENZYME: Q4 EBITDA 633M RUPEES VS 457M (YOY) || Q4 EBITDA MARGIN 31.12% VS 27.33% (YOY) ADVANCED ENZYME: BOARD RECOMMENDS A FINAL DIVIDEND OF ₹1.35 PER EQUITY SHARE